SCHEMBL2015357

SCHEMBL2015357

CCC1CCCCN1c1nnc(-c2ccc(O)cc2C)c2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
HTT P42858 5/20 0.44
HIF1A Q16665 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 4/20 0.42
HPGD P15428 3/20 0.42
NR1I2 O75469 1/20 0.41
SMARCA2 P51531 1/20 0.41
SMARCA4 P51532 1/20 0.41
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
PBRM1 Q86U86 1/20 0.41
MEN1 O00255 6/20 0.41
KMT2A Q03164 6/20 0.41
LMNA P02545 3/20 0.41
KDM4E B2RXH2 1/20 0.41
NPY5R Q15761 1/20 0.41
MAP2K7 O14733 1/20 0.39
NPSR1 Q6W5P4 7/20 0.39
MAPK1 P28482 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2022390 0.81 MAPT (0.45) MAPTHTTHIF1AL3MBTL1ALDH1A1
SCHEMBL2016584 0.77 DRD2 (0.37) MAPTHTTALDH1A1MEN1KMT2A
SCHEMBL2020667 0.74 SMO (0.45) MAPTHTTHIF1AL3MBTL1NPY5R
SCHEMBL2024183 0.74 DRD2 (0.36) MAPTHTTALDH1A1MEN1KMT2A
SCHEMBL12574572 0.73 SMO (0.38) MAPTHTTALDH1A1MEN1KMT2A
SCHEMBL2019540 0.73 ESR1 (0.42) MAPTHTTALDH1A1MEN1KMT2A
SCHEMBL2018489 0.71 SMO (0.43) MAPTHTTALDH1A1HPGDMEN1
SCHEMBL2017611 0.71 S1PR1 (0.42) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL2021567 0.69 TYR (0.42) MAPTALDH1A1HPGDMEN1KMT2A
SCHEMBL27848437 0.66 MAPT (0.45) MAPTHPGDNR1I2SMARCA2SMARCA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US claimed
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines MMP25, MMP9, MMP3 MAPT 3362/4885HTT 3469/4885HIF1A 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.